PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Texas Instruments Incorporated (TXN)
205.980.01 (0.00%)
205.24 - 207.41
139.95 - 221.69
4.54M / 6.54M (Avg.)
37.59 | 5.48
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
10.89%
Revenue growth above 1.5x MRVL's 7.04%. David Dodd would confirm if the firm has a unique advantage driving sales higher.
14.06%
Gross profit growth above 1.5x MRVL's 9.12%. David Dodd would confirm if the company's business model is superior in terms of production costs or pricing.
32.73%
EBIT growth above 1.5x MRVL's 20.91%. David Dodd would confirm if core operations or niche positioning yield superior profitability.
32.73%
Operating income growth above 1.5x MRVL's 20.91%. David Dodd would confirm if consistent cost or pricing advantages drive this outperformance.
308.03%
Net income growth above 1.5x MRVL's 21.67%. David Dodd would check if a unique moat or cost structure secures superior bottom-line gains.
316.22%
EPS growth above 1.5x MRVL's 16.67%. David Dodd would review if superior product economics or effective buybacks drive the outperformance.
316.67%
Diluted EPS growth above 1.5x MRVL's 30.00%. David Dodd would see if there's a robust moat protecting these shareholder gains.
-2.02%
Share reduction while MRVL is at 0.76%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
-1.98%
Reduced diluted shares while MRVL is at 0.76%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
-0.07%
Dividend reduction while MRVL stands at 0.00%. Joel Greenblatt would question the firm’s cash flow stability or capital allocation decisions.
14.72%
OCF growth under 50% of MRVL's 62.73%. Michael Burry might suspect questionable revenue recognition or rising costs.
77.85%
FCF growth similar to MRVL's 83.50%. Walter Schloss would attribute it to parallel capital spending and operational models.
50.46%
10Y revenue/share CAGR under 50% of MRVL's 374.41%. Michael Burry would suspect a lasting competitive disadvantage.
109.30%
5Y revenue/share CAGR under 50% of MRVL's 374.41%. Michael Burry would suspect a significant competitive gap or product weakness.
75.93%
3Y revenue/share CAGR under 50% of MRVL's 176.11%. Michael Burry might see a serious short-term decline in relevance vs. the competitor.
278.11%
10Y OCF/share CAGR under 50% of MRVL's 1571.84%. Michael Burry would worry about a persistent underperformance in cash creation.
25.75%
Below 50% of MRVL's 1571.84%. Michael Burry would be alarmed about sustained underperformance in generating free operational cash.
88.16%
3Y OCF/share CAGR under 50% of MRVL's 4458.54%. Michael Burry would worry about a significant short-term disadvantage in generating operational cash.
2966.45%
Net income/share CAGR at 50-75% of MRVL's 4742.96%. Martin Whitman might question if the firm’s product or cost base lags behind.
1497.30%
Below 50% of MRVL's 4742.96%. Michael Burry would worry about a substantial lag vs. the competitor’s profit ramp-up.
2095.75%
3Y net income/share CAGR above 1.5x MRVL's 801.58%. David Dodd would confirm the company’s short-term strategies outmatch the competitor significantly.
191.78%
Below 50% of MRVL's 679.61%. Michael Burry would suspect poor capital allocation or persistent net losses eroding long-term equity build-up.
16.42%
Below 50% of MRVL's 679.61%. Michael Burry sees a substantially weaker mid-term book value expansion strategy in place.
30.08%
3Y equity/share CAGR above 1.5x MRVL's 15.55%. David Dodd verifies the company’s short-term capital management far exceeds the competitor’s pace.
42.42%
Dividend/share CAGR of 42.42% while MRVL is zero. Bruce Berkowitz sees a slight advantage in stepping up payouts steadily.
46.49%
Dividend/share CAGR of 46.49% while MRVL is zero. Bruce Berkowitz sees a minor advantage in stepping up distributions, even modestly.
41.39%
3Y dividend/share CAGR of 41.39% while MRVL is zero. Bruce Berkowitz sees a minor positive difference that could attract dividend-focused investors.
7.29%
AR growth well above MRVL's 2.47%. Michael Burry fears inflated revenue or higher default risk in the near future.
7.14%
Inventory growth well above MRVL's 0.85%. Michael Burry suspects overshooting production or weaker sell-through vs. the competitor.
13.46%
Asset growth above 1.5x MRVL's 5.12%. David Dodd checks if M&A or new capacity expansions are value-accretive vs. competitor's approach.
16.14%
BV/share growth above 1.5x MRVL's 3.44%. David Dodd confirms if consistent profit retention or fewer write-downs yield faster equity creation.
-86.48%
Both reduce debt yoy. Martin Whitman sees a broader sector shift to safer balance sheets or less growth impetus.
0.56%
R&D dropping or stable vs. MRVL's 1.76%. David Dodd sees near-term margin benefits if the product pipeline is already strong.
-0.71%
We cut SG&A while MRVL invests at 6.81%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.